 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 161Tb-DOTA-LM3 / Paul Scherrer Institute, University Hospital Basel
Enrollment open, Trial initiation date: Beta plus: Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (clinicaltrials.gov) - Mar 7, 2023
P1, N=16, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Apr 2023
- | 161Tb-DOTA-LM3 / Paul Scherrer Institute, University Hospital Basel
New P1 trial: Beta plus: Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (clinicaltrials.gov) - May 2, 2022
P1, N=16, Not yet recruiting, Sponsor: University Hospital, Basel, Switzerland